Assess Efficacy and Safety of AZD6244 in Combination with Docetaxel in Patients receiving second line NSCLC treatment

Mise à jour : Il y a 5 ans
Référence : EUCTR2012-003622-25

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

To assess the efficacy in terms of Progression-Free Survival (PFS) for each comparison of selumetinib in combination with docetaxel, compared to placebo in combination with docetaxel


Critère d'inclusion

  • Locally Advanced or Metastatic Non Small Cell Lung Cancer stage IIIb - IV